Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2022-01-03 Report Publication Anno…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that the company's CEO will present at an upcoming third-party conference (H.C. Wainwright Bioconnect 2022 Virtual Conference). It details the date and time the presentation will be available and where a replay can be found. This is not a full financial report (like 10-K or IR), an earnings release (ER), or a formal proxy/governance document. It is an announcement related to investor relations activities, specifically about an upcoming presentation. Since there is no specific category for 'Conference Presentation Announcement,' and it is an announcement about future investor engagement, it most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the content itself was attached. However, since the text only announces the *event* and the *availability* of the presentation, and given the short length (2562 chars), it fits best as a general regulatory announcement or a notice regarding investor communication. Given the options, RNS (Regulatory Filings) is the most appropriate fallback for general corporate news releases that don't fit specific financial reporting categories. If 'Investor Presentation' (IP) implied the announcement *of* the presentation, it could fit, but IP is usually for the presentation document itself. RNS serves as the best general announcement category here.
2022-01-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from MaaT Pharma announcing the company's participation in the H.C. Wainwright BioConnect 2022 virtual conference, including details about when the presentation will be accessible. This is not a full financial report (like 10-K or IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement related to investor relations activities, specifically concerning a presentation given at a conference. While it relates to investor information, the core purpose is announcing the event and presentation availability, which aligns best with a general Investor Presentation (IP) announcement or, given its nature as a brief announcement about an upcoming presentation, it could be considered a Regulatory Filing (RNS) if no better fit exists. However, since the content is entirely focused on an upcoming investor presentation, 'Investor Presentation' (IP) is the most specific fit, even though it's an announcement *about* the presentation rather than the presentation itself. Given the options, and recognizing this is a standard corporate communication about investor engagement, IP is the strongest candidate, although RPA (Report Publication Announcement) is also plausible if we strictly follow the 'announcement vs. report' rule. Since the document *is* the announcement of the presentation content/availability, and not the presentation slides themselves, I will lean towards the most specific category related to investor events, which is IP, or the general announcement category RPA. Since it's announcing an event where an IP will be given, and the text itself is a press release, RPA (Report Publication Announcement) fits the 'announcement' nature better than IP (which usually refers to the slides/deck). However, looking closely at the definitions, IP is for the presentation itself. This is an announcement *about* the presentation. Given the short length and the nature of announcing an event/presentation, RPA is a strong fit, but RNS is the ultimate fallback. Let's re-evaluate: It's an announcement about an investor presentation. If the presentation slides were attached, it would be IP. Since it's just the press release announcing the presentation, RPA (Report Publication Announcement) is the most accurate fit for announcing the availability/event related to investor materials.
2022-01-03 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "COMMUNIQUE DE PRESSE Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Press Release Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation and provides a table detailing the total number of shares and voting rights as of January 3, 2022. This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement in France. While it is a regulatory announcement, it does not fit the definition of a standard 10-K, IR, or ER. It is a specific notification about the capital structure. Among the provided codes, this content most closely aligns with a general regulatory filing or announcement. Since there is no specific code for 'Share Capital/Voting Rights Disclosure', and it is a formal regulatory communication, it falls best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA). However, since it is a routine monthly update on existing capital structure rather than a new issue or change announcement, RNS (Regulatory Filings) is the most appropriate fallback for a specific, non-standard regulatory disclosure.
2022-01-03 French
Déclaration Actionnariat Janvier 22
Share Issue/Capital Change Classification · 95% confidence The document is titled "COMMUNIQUE DE PRESSE Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Press Release Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of a specific date (03/01/2022). This content directly relates to mandatory disclosures concerning the company's capital structure and voting power, which is a specific type of regulatory announcement. While it is a regulatory filing, the specific nature of reporting share capital and voting rights aligns most closely with disclosures related to share structure changes or major ownership notifications, but given the options, it is a mandatory periodic disclosure. Since it is a formal announcement of a specific metric (voting rights/share count) required by the AMF, and it is not a general earnings release (ER), a major shareholding notification (MRQ - which usually reports *changes* by an external party crossing a threshold), or a transaction in own shares (POS - which reports buybacks/sales), the most appropriate general category for mandatory, periodic regulatory updates that don't fit elsewhere is 'Regulatory Filings' (RNS). However, looking closely at the definitions, 'Share Issue/Capital Change' (SHA) covers capital structure changes. Since this is a periodic report on the *current* capital structure and voting rights, it is a specific regulatory disclosure. Given the options, and the fact that it is a mandatory disclosure about the capital base, it is a regulatory filing. If a more specific code existed for 'Share Capital/Voting Rights Disclosure', that would be ideal. In the absence of that, RNS serves as the best fit for mandatory, non-financial periodic regulatory updates that aren't explicitly covered by other codes like 10-K or ER. The document length is short (3768 chars), but it is the report itself, not an announcement of a report, so the RPA rule does not strictly apply here, as this *is* the required disclosure document.
2022-01-03 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release dated December 11, 2021, announcing clinical trial results (Phase 2 HERACLES and compassionate use data for MaaT013) presented at the 63rd annual meeting of the American Society of Hematology (ASH). Crucially, it also announces a webcast for investors to discuss these results on December 13th. Since the document primarily releases key financial/clinical highlights and schedules an investor event, it fits the definition of an Earnings Release (ER) or potentially an Investor Presentation (IP) if it were the slides themselves. However, the structure—announcing results and immediately scheduling a call to discuss them—is characteristic of an Earnings Release (ER) which provides the initial announcement of periodical financial/clinical performance highlights. It is not the full Annual Report (10-K) or a comprehensive Interim Report (IR). It is also not just an announcement of a report publication (RPA) because it contains the substantive data itself. FY 2021
2021-12-11 French
Inside Information / Other news releases
Earnings Release Classification · 99% confidence The document is a press release dated December 11, 2021, announcing clinical data presentation at the 63rd ASH Annual Meeting and providing key results from the HERACLES Phase 2 trial and an Early Access Program (EAP) for MaaT013. It details clinical response rates (GI-ORR) and survival data. Crucially, it announces a corporate webcast to discuss these results and provides corporate background. This structure—announcing new data/results and scheduling an investor call—is characteristic of an Earnings Release (ER) or a general press release detailing significant operational/clinical updates. Since it focuses on the *release* of clinical data and subsequent investor discussion rather than being a comprehensive annual/interim report (10-K or IR), 'ER' is the most appropriate fit among the options, as it serves as the initial announcement of period-specific performance/data highlights. It is not a transcript (CT), a formal annual report (10-K), or just a notice of a report publication (RPA). FY 2021
2021-12-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.